Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ATM
Variant R2227C
Impact List missense
Protein Effect loss of function - predicted
Gene Variant Descriptions ATM R2227C lies within the FAT domain of the Atm protein (UniProt.org). R2227C results in reduced Atm protein expression, and increased radiosensitivity of cultured cells (PMID: 18634022), and therefore, is predicted to lead to a loss of Atm protein function.
Associated Drug Resistance
Category Variants Paths

ATM mutant ATM inact mut ATM R2227C

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000051.4
gDNA chr11:g.108325416C>T
cDNA c.6679C>T
Protein p.R2227C
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_011542843.3 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
XM_047426976.1 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
NM_001351834.2 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
XM_047426975.1 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
NM_000051.4 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
XM_006718843.5 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
XM_005271562.6 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
XM_017017790.3 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38
XM_011542840.4 chr11:g.108325416C>T c.6679C>T p.R2227C RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATM R2227C prostate cancer sensitive Olaparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) improved progression-free survival (7.4 vs 3.6 mo, HR 0.34, p<0.001), objective response rate (33% vs 2%, OR 20.86, p<0.001), and median overall survival (18.5 vs 15.1 mo, HR 0.64, p=0.02) over control in metastatic prostate cancer patients harboring inactivating BRCA/ATM mutations as detected by approved assays, including ATM R2227C, HR was 1.04 in ATM-mutant group (PMID: 32343890; NCT02987543). detail... 32343890 detail...